Teratogenic Effects of Phenytoin and Antenatal Care
Phenytoin carries significant teratogenic risks including a 10% rate of major congenital malformations (2-3 fold higher than the general population), and pregnant women taking phenytoin require intensive monitoring with serial phenytoin levels, detailed anatomical ultrasound, vitamin K supplementation before delivery, and neonatal vitamin K administration to prevent life-threatening hemorrhagic disease of the newborn. 1
Teratogenic Effects
Major Malformations
Prenatal phenytoin exposure causes a well-defined pattern of birth defects:
- Orofacial clefts (cleft lip/palate)
- Cardiac defects
- Overall malformation rate: ~10% (compared to 3-5% in general population) 1
Fetal Hydantoin Syndrome
This syndrome occurs in 10-30% of exposed infants and includes 2:
- Craniofacial abnormalities (dysmorphic facial features)
- Limb defects (nail and digit hypoplasia)
- Pre/postnatal growth deficiency (including microcephaly)
- Mental deficiency
Neurodevelopmental Effects
Phenytoin exposure significantly impairs cognitive development 3:
- Lower Performance IQ, Full Scale IQ, and visual-motor integration scores
- These effects persist into childhood (ages 4-8 years)
- Cognitive impairments occur even in children without overt malformations
Neonatal Complications
Life-threatening hemorrhagic disease can occur in newborns due to decreased vitamin K-dependent clotting factors 1
Other Reported Risks
Essential Antenatal Care and Assessment
Pre-Conception Counseling
- Inform patients of the 2-3 fold increased malformation risk before pregnancy
- Discuss risk-benefit balance of continuing phenytoin versus seizure control
- Consider switching to lower-risk alternatives (lamotrigine, levetiracetam) if clinically appropriate 5
Monitoring During Pregnancy
Pharmacokinetic Management:
- Measure plasma phenytoin concentrations periodically throughout pregnancy 1
- Seizure frequency may increase due to altered phenytoin pharmacokinetics
- Dosage adjustments are often necessary during pregnancy
- Plan for postpartum restoration of original dosage
Fetal Surveillance:
- Detailed anatomical ultrasound at 18-20 weeks focusing on:
- Cardiac structures (for congenital heart defects)
- Facial structures (for orofacial clefts)
- Limb development (for digit/nail hypoplasia)
- Growth parameters (for microcephaly and growth restriction)
- Serial growth ultrasounds in third trimester
Maternal Vitamin K Supplementation:
- Administer vitamin K to the mother before delivery to prevent neonatal hemorrhagic disease 1
- This is critical and potentially life-saving
Neonatal Management
Immediate Postnatal Care:
- Administer vitamin K to the neonate immediately after birth 1
- Monitor for bleeding complications
- Assess for dysmorphic features consistent with Fetal Hydantoin Syndrome
- Evaluate for major malformations (cardiac, orofacial)
Long-term Follow-up:
- Neurodevelopmental assessment during childhood
- Monitor for cognitive and behavioral problems
- Early intervention services if developmental delays identified
Critical Clinical Caveats
The dose-dependent nature of phenytoin teratogenicity means higher doses carry greater risk, though even therapeutic doses pose significant danger 5. The evidence does not allow precise attribution of risk to phenytoin alone versus epilepsy itself, but the FDA labeling clearly establishes phenytoin as a causative factor 1.
Common pitfall: Failing to administer maternal and neonatal vitamin K prophylaxis—this omission can result in preventable neonatal death from hemorrhage.
Important distinction: While the guideline evidence 6 addresses neonatal seizure treatment, it does not provide guidance on managing pregnant women taking phenytoin. The FDA drug labeling 1 serves as the primary authoritative source for pregnancy management.